文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development.

作者信息

Yee Douglas, Haddad Tufia, Albain Kathy, Barker Anna, Benz Christopher, Boughey Judy, Buxton Meredith, Chien Amy Jo, DeMichele Angela, Dilts David, Elias Anthony, Haluska Paul, Hogarth Michael, Hu Alan, Hytlon Nola, Kaplan Henry G, Kelloff Gary G, Khan Qamar, Lang Julie, Leyland-Jones Brian, Liu Minetta, Nanda Rita, Northfelt Donald, Olopade Olufunmilayo I, Park John, Parker Barbara, Parkinson David, Pearson-White Sonia, Perlmutter Jane, Pusztai Lajos, Symmans Fraser, Rugo Hope, Tripathy Debu, Wallace Anne, Wholley David, Van't Veer Laura, Berry Donald A, Esserman Laura

出版信息

J Clin Oncol. 2012 Dec 20;30(36):4584-6; author reply 4588-9. doi: 10.1200/JCO.2012.44.1022. Epub 2012 Nov 19.

DOI:10.1200/JCO.2012.44.1022
PMID:23169510
Abstract
摘要

相似文献

[1]
Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development.

J Clin Oncol. 2012-12-20

[2]
Defining the benefits of neoadjuvant chemotherapy for breast cancer.

J Clin Oncol. 2012-5-20

[3]
Advocates' perspective: neoadjuvant chemotherapy for breast cancer.

J Clin Oncol. 2012-12-20

[4]
Strategy for nonresponder breast cancer patients to neoadjuvant treatment.

Ann Surg Oncol. 2011-12

[5]
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

J Clin Oncol. 2012-4-16

[6]
[Cancer of the breast after Hodgkin's disease. Analysis of 6 cases].

Presse Med. 1993-12-4

[7]
Dedicated Breast Positron Emission Tomography for the Evaluation of Early Response to Neoadjuvant Chemotherapy in Breast Cancer.

Clin Breast Cancer. 2017-6

[8]
Once more in St. Gallen.

Ann Oncol. 1998-5

[9]
Negative genic switch of HER-2 in the primary tumor instead of the synchronous metastatic nodal lesions after neoadjuvant chemotherapy in a patient with primary HER2-positive breast cancer.

World J Surg Oncol. 2017-10-19

[10]
Are there changes in characteristics and therapy of young patients with early-onset breast cancer in Germany over the last decade?

Arch Gynecol Obstet. 2013-2-14

引用本文的文献

[1]
"It's personalized, but it's still bucket based": The promise of personalized medicine vs. the reality of genomic risk stratification in a breast cancer screening trial.

New Genet Soc. 2022

[2]
PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms.

Clin Pharmacol Ther. 2016-12

[3]
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.

N Engl J Med. 2016-7-7

[4]
Can we unlock the potential of IGF-1R inhibition in cancer therapy?

Cancer Treat Rev. 2014-10

[5]
Achieving integration in mixed methods designs-principles and practices.

Health Serv Res. 2013-10-23

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索